Type 1 diabetes mellitus adverse event reports that record this term

Kind of term: MedDRA preferred term
Plain meaning: type 1 diabetes

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From November 2004 to June 2026, FDA received 5,931 adverse event reports that record the MedDRA preferred term Type 1 diabetes mellitus. In plain words, the term means: type 1 diabetes. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 401 reports in the 12 months to June 2026 and 402 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,105 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 401 (under 0.1%) record this term. Reports for male patients were 44.6% of the reports that record this term and 34.6% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Plain meaning

Type 1 diabetes. The words are from the fixed dictionary of this site. They add nothing to a report.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 135 drug pages with 10 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Type 1 diabetes mellitus name as a suspect product, in order of name
Drug	Class	Reports with this term
Abilify	Atypical antipsychotic	53
Acetaminophen		32
Actemra	Interleukin-6 receptor antagonist	28
Afinitor	Kinase inhibitor	11
Alendronate sodium	Bisphosphonate	10
Apixaban	Factor Xa inhibitor	17
Aripiprazole	Atypical antipsychotic	16
Atezolizumab	Programmed death Receptor-1 blocking antibody	71
Atorvastatin		10
Atorvastatin calcium	HMG-CoA reductase inhibitor	16
Avastin	Vascular endothelial growth factor inhibitor	50
Avonex	Interferon beta	39
Azathioprine	Purine antimetabolite	49
Bactrim	Dihydrofolate reductase inhibitor antibacterial	18
Benlysta	B lymphocyte stimulator-specific inhibitor	35
Bevacizumab	Vascular endothelial growth factor inhibitor	35
Bromazepam		11
Byetta	GLP-1 receptor agonist	14
Cabometyx	Kinase inhibitor	15
Capecitabine	Nucleoside metabolic inhibitor	16
Carboplatin	Platinum-based drug	86
CellCept	Antimetabolite immunosuppressant	10
Chantix	Partial cholinergic nicotinic agonist	13
Cimzia	Tumor necrosis factor blocker	24
Cisplatin	Platinum-based drug	34
Clozapine	Atypical antipsychotic	21
Clozaril	Atypical antipsychotic	16
Copegus		11
Cosentyx	Interleukin-17A antagonist	26
Creon		49
Crestor	HMG-CoA reductase inhibitor	22
Cyclophosphamide	Alkylating drug	61
Cyclosporine	Calcineurin inhibitor immunosuppressant	20
Dapagliflozin	Sodium-Glucose cotransporter 2 inhibitor	11
Dapsone	Sulfone	35
Depakote	Anti-epileptic agent	21
Dexamethasone	Corticosteroid	40
Diphenhydramine	Histamine-1 receptor antagonist	24
Doxorubicin	Anthracycline topoisomerase inhibitor	13
Dupixent	Interleukin-4 receptor alpha antagonist	42
Durvalumab	Programmed death Ligand-1 blocker	28
Enbrel	Tumor necrosis factor blocker	125
Enfortumab vedotin		17
Entresto	Angiotensin 2 receptor blocker	15
Etoposide	Topoisomerase inhibitor	14
Ezetimibe	Dietary cholesterol absorption inhibitor	13
Fosamax	Bisphosphonate	30
Humalog	Insulin analog	26
Human immunoglobulin g	Human immunoglobulin G	10
Humira		140
Hydrocortisone	Corticosteroid	23
Hydroxychloroquine	Antimalarial	59
Hydroxychloroquine sulfate	Antimalarial	37
Iclusig	Kinase inhibitor	10
Imfinzi	Programmed death Ligand-1 blocker	34
Inlyta	Kinase inhibitor	13
Insulin	Insulin analog	20
Insulin glargine	Insulin analog	14
Ipilimumab	CTLA-4-directed blocking antibody	200
Irbesartan	Angiotensin 2 receptor blocker	10
Isotretinoin	Retinoid	17
Janumet	Biguanide	12
Januvia	Dipeptidyl peptidase 4 inhibitor	38
Jardiance	Sodium-Glucose cotransporter 2 inhibitor	19
Keytruda	Programmed death Receptor-1 blocking antibody	512
Lamotrigine	Anti-epileptic agent	12
Lantus	Insulin analog	21
Leflunomide	Antirheumatic agent	56
Lenvatinib mesylate		18
Lenvima	Kinase inhibitor	93
Levothyroxine		10
Levothyroxine sodium	l-Thyroxine	32
Lipitor	HMG-CoA reductase inhibitor	21
Lyrica		21
Metformin	Biguanide	24
Methotrexate	Folate analog metabolic inhibitor	84
Methylprednisolone	Corticosteroid	49
Methylprednisolone sodium succinate	Corticosteroid	27
Minocycline	Tetracycline-class drug	14
Mirena	Progestin	10
Mycophenolate mofetil	Antimetabolite immunosuppressant	83
Nexium	Proton pump inhibitor	43
Nivolumab	Programmed death Receptor-1 blocking antibody	339
Norditropin	Recombinant human growth hormone	10
Novolog	Insulin analog	13
Novorapid		13
Olanzapine	Atypical antipsychotic	57
Omeprazole	Proton pump inhibitor	14
Opdivo	Programmed death Receptor-1 blocking antibody	320
Oxycodone and acetaminophen	Opioid agonist	10
Oxycodone hydrochloride	Opioid agonist	19
OxyContin	Opioid agonist	24
Ozempic	GLP-1 receptor agonist	16
Paclitaxel	Microtubule inhibitor	62
Pantoprazole	Proton pump inhibitor	10
Peg-Intron		15
Pegasys	Interferon alpha	14
Pembrolizumab	Programmed death Receptor-1 blocking antibody	169
Pemetrexed	Folate analog metabolic inhibitor	44
Plaquenil	Antimalarial	16
Prednisolone	Corticosteroid	84
Prednisone	Corticosteroid	141
Prevacid	Proton pump inhibitor	19
Prilosec	Proton pump inhibitor	13
Prograf	Calcineurin inhibitor immunosuppressant	11
Prolia	RANK ligand inhibitor	13
Ramipril	Angiotensin converting enzyme inhibitor	41
Rebetol		23
Rebif	Interferon beta	33
Remicade	Tumor necrosis factor blocker	29
Ribavirin	Nucleoside analog antiviral	34
Rinvoq	Janus kinase inhibitor	17
Risperdal	Atypical antipsychotic	59
Risperidone	Atypical antipsychotic	20
Rituximab	CD20-directed cytolytic antibody	69
Rosuvastatin	HMG-CoA reductase inhibitor	15
Saizen		14
Seroquel	Atypical antipsychotic	738
Singulair	Leukotriene receptor antagonist	20
Skyrizi	Interleukin-23 antagonist	11
Soliris	Complement inhibitor	10
Somatropin	Recombinant human growth hormone	13
Sulfasalazine	Aminosalicylate	26
Tacrolimus	Calcineurin inhibitor immunosuppressant	55
Tecentriq	Programmed death Receptor-1 blocking antibody	99
Tecfidera		54
Tepezza		21
Tysabri	Integrin receptor antagonist	32
Vincristine		15
Xeplion		10
Xolair	Anti-IgE	26
Yervoy	CTLA-4-directed blocking antibody	151
Zoloft	Serotonin reuptake inhibitor	10
Zopiclone		11
Zyprexa	Atypical antipsychotic	154

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 46 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Type 1 diabetes mellitus name, in order of name
Class	Reports with this term
Alkylating drug	63
Aminosalicylate	26
Angiotensin 2 receptor blocker	27
Angiotensin converting enzyme inhibitor	52
Anti-epileptic agent	53
Anti-IgE	32
Antimalarial	112
Antimetabolite immunosuppressant	95
Antirheumatic agent	58
Atypical antipsychotic	1,163
B lymphocyte stimulator-specific inhibitor	37
Biguanide	38
Bisphosphonate	46
Calcineurin inhibitor immunosuppressant	90
CD20-directed cytolytic antibody	81
Corticosteroid	384
CTLA-4-directed blocking antibody	362
Dipeptidyl peptidase 4 inhibitor	38
Folate analog metabolic inhibitor	130
GLP-1 receptor agonist	52
Histamine-1 receptor antagonist	39
HMG-CoA reductase inhibitor	80
Insulin analog	116
Integrin receptor antagonist	41
Interferon beta	72
Interleukin-17A antagonist	26
Interleukin-4 receptor alpha antagonist	48
Interleukin-6 receptor antagonist	32
Janus kinase inhibitor	35
Kinase inhibitor	184
l-Thyroxine	39
Microtubule inhibitor	67
Nucleoside analog antiviral	34
Nucleoside metabolic inhibitor	37
Opioid agonist	98
Platinum-based drug	126
Programmed death Ligand-1 blocker	69
Programmed death Receptor-1 blocking antibody	1,518
Proton pump inhibitor	139
Purine antimetabolite	49
Recombinant human growth hormone	28
Serotonin reuptake inhibitor	26
Sodium-Glucose cotransporter 2 inhibitor	39
Sulfone	35
Tumor necrosis factor blocker	217
Vascular endothelial growth factor inhibitor	85

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Type 1 diabetes mellitus, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Type 1 diabetes mellitus
Age	Reports	Share
Under 2	21	0.4%
2 to 11	175	3%
12 to 17	260	4.4%
18 to 44	1,133	19.1%
45 to 64	1,505	25.4%
65 to 74	682	11.5%
75 and over	374	6.3%
Age not given	1,781	30%

Sex of the patient in the reports that record Type 1 diabetes mellitus
Sex	Reports	Share
Female	2,788	47%
Male	2,648	44.6%
Unknown or not given	495	8.3%

Age and sex are as the report gives them. 52.3% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Type 1 diabetes mellitus: adverse event reports that record this term. https://reportedreactions.com/reaction/type-1-diabetes-mellitus/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Type 1 diabetes mellitus mean in an adverse event report?

In plain words: type 1 diabetes. It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page